40mg Olmesartan and 5mg Amlodipine
Jun 10, 2023
Olmistrum AM 40
Olmesartan 40 mg and Amlodipine 5 mg are two different medications often prescribed together for the treatment of hypertension (high blood pressure). This combination is often referred to as a fixed-dose combination or a single-pill combination.
Olmesartan is an angiotensin II receptor blocker (ARB) that helps relax blood vessels, reducing blood pressure. It works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow.
Amlodipine is a calcium channel blocker (CCB) that also helps relax blood vessels and improve blood flow. It works by inhibiting the entry of calcium into the smooth muscle cells of blood vessels, leading to their relaxation.
Combining Olmesartan and Amlodipine provides additive or synergistic effects in lowering blood pressure, making it more effective in managing hypertension compared to either medication alone.
The standard dosage for this combination therapy is Olmistrum AM 40 taken orally once daily. However, the actual dosage may vary depending on the individual's condition, response to the medication, and the doctor's recommendations. It is important to follow your doctor's instructions regarding the dosage and frequency of administration.
For further information please contact:
contact@sterispharma.com
order now sterisonline.com
Recent Post
Vonoprazan 10/20 mg
Best Serum जो चेहरे के दाग-धब्बे मिटाए ..
Managing Hypertension and Angina with DILTIAZONE CD 120: Benefits and Dosage
DILTIAZONE CD 90: A Comprehensive Guide to Diltiazem Hydrochloride Extended Release 90 mg
Your Baby’s Comfort Starts with EUROSOFT Nappy Rash Cream
Keep Your Intimate Area Clean and Fresh with Eurosoft Intimate Wash PHMatter
Glycerine, Aloe Vera, and Shea Butter: The Key Ingredients in EUROSOFT Wild Berry Lotion
Lightweight Yet Hydrating: The Best Lotion for Oily and Dry Skin Alike
Eurosoft Intimate Wash PHMatter: Your Key to Maintaining Hygiene and Comfort
Katarina Shampoo 2%: A Dermatologist-Recommended Choice for Scalp Issues